It has been hypothesised that buccal administration of testosterone (T), by preventing first-pass catabolism by the liver, may be a viable alternative to gels, patches and injectables. This abstract compares the pharmacokinetic/clinical pharmacological profiles of several routes of administration. Two studies were undertaken. In both Striant (30mg testosterone buccal system) was administered twice daily (at circa 08.00 and 22.00). In one 14-day, open label study in 26 hypogonadal males at 4 sites a comparison was made with Androgel (5g containing 50mg T ), daily. In the second in 67 patients at 5 sites the comparison was with Androderm (5mg) and /or Andropatch (5mg) for 7 days.
Recorded in June 2011 at the 20th WAS World Congress for Sexual Health
Forging the Future: Sexual Health for the 21st Century, Glasgow, UK.
The World Association Of Sexual Health at http://www.worldsexology.org